Comparing Dapagliflozin and Pentoxifylline for Chronic Kidney Disease
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
This study is testing whether the medication Dapagliflozin works better than Pentoxifylline to help protect kidney function in people with chronic kidney disease.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 210 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06421870 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the renoprotective effects of Dapagliflozin compared to Pentoxifylline in patients with chronic kidney disease (CKD) stages 2 and 3. The study aims to evaluate how these medications impact kidney function, particularly focusing on glomerular filtration rate (GFR) and the progression of renal complications. By utilizing a phase 3 interventional approach, the trial will assess the efficacy and safety of these treatments in slowing kidney function decline. Participants will receive either Dapagliflozin or Pentoxifylline to determine which medication offers better protection against kidney damage.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with chronic kidney disease stages 2 and 3 who do not have diabetes.
Not a fit: Patients with diabetes mellitus or those with a history of recurrent genitourinary infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option that significantly slows the progression of chronic kidney disease.
How similar studies have performed: Previous studies have shown promising results with SGLT2 inhibitors in managing kidney disease, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CKD stage 2 and 3 Exclusion Criteria: * Diabetes mellitus * History of recurrent or recent genitourinary infections * Immunosuppressive medications * Malignancy
Where this trial is running
Cairo
- Ain Shams University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Mohamed A Mohamed, MSc
- Email: Mohammed.Ashraf@med.asu.edu.eg
- Phone: 1119090018
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.